Barclays Boosts Teva Price Target to $38 After Strong Quarterly Performance, Joining Analyst Optimism
Barclays and Scotiabank have raised their price targets for Teva Pharmaceutical following its better-than-expected Q4 2025 results and a key pediatric approval for its migraine drug AJOVY, signaling growing confidence in the generic drugmaker's turnaround trajectory.